Filing Flows › Supernus Pharmaceuticals (SUPN) › Stock forecast & fair value
Supernus Pharmaceuticals (SUPN) stock forecast and price target
Supernus Pharmaceuticals (SUPN) trades at $26.16. 6 analysts' median price target is $50.00 (+91%), from $45.00 to $87.00.
Supernus Pharmaceuticals' latest quarter
Supernus Pharmaceuticals, Q3 2026: revenue $227M (+18% year over year), operating margin 9.3%, net earnings $20.9M, operating cash flow $6.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for SUPN stock?
The median of 6 analysts' 12-month targets is $50.00, +91% from $26.16; the range is $45.00 to $87.00. The average rating is strong buy.
Does Supernus Pharmaceuticals usually beat earnings estimates?
It beat the consensus EPS estimate in 80% of the quarters on record.
Is SUPN stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.